Enara Bio

📍 Oxford, United Kingdom👥 67 employees💰 Last funded 2024
Biotechnology🌐 enarabio.com
Website LinkedIn
Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Through our proprietary EnTiCE platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Our partner, Boehringer Ingelheim, is combining multiple licensed Dark Antigens to create novel immunotherapies. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, SV Health Investors, and the Francis Crick Institute. For more information, visit: www.enarabio.com. Comments and DMs to this account are not monitored, for any further information please head to our website
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
1
United Kingdom
1
Switzerland
1
Investor activity2020–2024 · investors recorded per year
2020220241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Enara Bio?
Enara Bio has 3 investors on record on gritt.io.
When did Enara Bio last raise funding?
The most recent investment in Enara Bio recorded on gritt.io was in 2024.
What industry is Enara Bio in?
Enara Bio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Enara Bio based?
Enara Bio is headquartered in Oxford, United Kingdom.